The Work

A global CPG’s Life Sciences R&D team recognized that attracting the best biotech partners required more than scientific capability—it required a compelling story about why the company was the right partner.

Strategy + Tactics. Messaginglab worked with the company’s life sciences R&D team to refine their messaging and positioning, developing a narrative that would resonate with emerging biotech companies evaluating potential enterprise partners. The work focused on articulating the company’s unique history and value as a collaborator—the scale, the resources, and the commitment to biology-based innovation.

Results. The refined positioning established this company’s Life Sciences R&D division as a partner of choice for biotech companies seeking enterprise-scale collaboration, strengthening their pipeline of strategic partnerships with emerging innovators.

K18 is a biotechnology company that creates and markets hair care products. The company had started to market to consumers but wanted to increase the amount of science and biotech included in their consumer messaging.

As the future of consumer biotechnology, K18 came to messagingLAB to make the science behind their products accessible to customers.

Strategy + Tactics. Messaginglab has become a part of the core team at K18. We have researched the science behind the product. Messaginglab has told the story behind the science by providing several science-based pieces around hair damage, strength, elasticity, and others. In addition, Messaginglab provided thought leadership messaging for the CEO and suggested biotech conferences to attend.

Results. As a result of Messaginglab’s work, K18 has published well-received science-based blogs about their products. Their Instagram and TikTok content also includes this science content, saturating the market with the biotech and science stories that power the K18 brand.

For Novartis Vaccines & Diagnostics, Messaginglab served as internal communications counsel during the divestiture of the business to GlaxoSmithKline. The challenge was to inspire employees and keep them focused on producing excellence during a year-long emotional transition.

Strategy + Tactics. Messaginglab developed content that highlighted the company’s scientific discoveries and profiled corporate leaders dedicated to continuing to do their best work while awaiting the outcome of the divestiture.

We also wrote an internal blog for the Chief Scientific Officer, one of the world’s leading vaccinologists.

Results. Our content was considered the most engaging and widely read on Novartis’ internal website based on traffic and comments.

Boston Consulting Group partnered with Messaginglab to produce a landmark report on the intersection of biology, design, and industry.

Strategy + Tactics. Messaginglab drafted the Nature Codesign report in collaboration with BCG, bringing deep bioeconomy expertise and narrative craft to one of the world's leading strategy consultancies. The report explored how companies can work with biological systems—rather than against them—to redesign products, processes, and supply chains.

Results. The Nature Codesign report positioned BCG at the forefront of the biology-as-technology conversation, providing enterprise leaders with a strategic framework for integrating biological design principles into their businesses.

The Advanced Biotech for Sustainability (AB4S) coalition brought together some of the world's most influential companies to articulate a shared vision for the future of molecular biomanufacturing.

Strategy + Tactics. Messaginglab worked alongside McKinsey, L'Oréal, Lallemand, Evonik, and Cradle to write The Molecule Manifesto—a foundational document making the case for scaled biomanufacturing and its potential to transform global supply chains. Messaginglab brought narrative strategy and scientific communications expertise to a coalition of industry leaders, helping translate complex technical and economic arguments into a clear, compelling call to action.

Results. The Molecule Manifesto established a shared language and strategic framework for cross-industry collaboration on biomanufacturing, uniting major players from consulting, consumer goods, ingredients, specialty chemicals, and biotech around a common vision for the biologicalization of industry.

Polybion is growing premium, next-generation materials designed with nature and manufactured with biology. Polybion uses waste as a raw material, and designs, produces, and finishes its bioassembled products under the same roof to increase sustainability and drive the circular economy. Polybion came to Messaginglab to improve their brand messaging and media relations strategies.

Strategy + Tactics. Messaginglab connected Polybion with a branding agency and aided in the creation and distribution of their $4.4 million Series A fundraising press release.

Results. The press release received media coverage from 350+ outlets including Forbes and Genetic Engineering and Biotechnology News and generated social media attention from sustainability and biomaterial-focused industry leaders. Following the release, Polybion was asked to speak at the biomaterial industry-focused Biofabricate Summit. The Messaginglab team has a strong professional relationship with Polybion and continues to offer them counsel on communications and public relations.

Bota Bio is a US/Chinese integrated bio-manufacturing platform that provides organism engineering services to companies in the materials, nutrition, and agricultural spaces. This Chinese-based biotech startup is a small, pioneering company looking to move from under the radar to make headlines.

Strategy + Tactics. The company had just raised $100 million in series B funding and wanted to tell the world about this funding. To attract high-level talent and get Bota Bio on the map, Messaginglab developed the messaging for the announcement. We aided in improving clarity around their messaging, including minor refinements to their website. We drafted the press release and provided media training for the CEO and an additional team member.

Results. Bota Bio's Series B announcement received original coverage by Reuters, Forbes, BioCentury, Endpoints, C&EN, BioSpace, Drug Discovery Trends, Crunchbase, VC News Daily, VC Journal, and Law360. On the day of the release, 147 outlets posted our release for a total estimated audience reach of 130.7 million. In addition, the information went viral on Twitter, gaining an even wider spread.

Core Biogenesis is a biomanufacturing company that uses plants to scale the production of recombinant proteins. Their Ultra-scalable bioproduction as a service platform accelerates mass production and increases yields while driving down costs.

After receiving its seed round of funding, Core Biogenesis wanted to refine its message and website to recruit talent and be ready for its Series A funding later that year.

Strategy + Tactics. Messaginglab developed a communications roadmap for Core Biogenesis. We did a story workshop to work with the brand to develop and refine messages. We worked with Transfuture to develop an updated website to provide this messaging and information about bio geneticists and their technology. We also drafted a foundational blog post the company has been using for sales and business development efforts.

Results. Core Biogenesis expressed their appreciation for the great work delivered in time. As a result, they have increased their staff size and have received inquiries into their business. Their message for biotech founders: "Messaginglab is your partner of choice to craft and hone your messaging strategy."

Micropep Technologies is a French agricultural biotech company leveraging the power of computational biology and artificial intelligence to identify micropeptides to control plant growth. The company’s complex story needed to be simplified to attract investors.

Strategy + Tactics. Messaginglab developed the company’s positioning, drafted key messages and FAQs, and provided counsel on the company’s funding deck. In addition, Messaginglab introduced the company to several potential investors for its Series A fundraise.

Results. The company’s story has been well received. Micropep subsequently raised €8.75 million in a Series A1 financing round.

Asimov develops software to create biological circuits. The company’s technology can help biotechnology companies better manufacture a product and create novel, biological tools.

Strategy + Tactics. Messaginglab used Asimov's funding announcement to start a conversation about biocircuit design and its potential.

We defined launch messages, wrote the media release, and helped craft corporate and funder blog posts. We also conducted media training and identified and pre-pitched reporters. On launch day, we conducted media outreach.

Results. The launch generated media coverage in BioFuels Digest, BostonInno, Boston Biz Journal, Fortune, Healthcare Analytics News, Industrial Biotech, TechCrunch and TechCrunch Japan, Techstartups, SynBioBeta, WBZ (radio), Wired, and Xconomy. In addition, the launch also resulted in inquiries from ten venture firms and five potential clients.

Degron Therapeutics is a biotechnology company advancing human health by developing a new class of targeted protein degradation medicines, using its molecular degradation drug discovery platform. As a new company founded in 2021, Degron Therapeutics came to Messaginglab seeking more visibility in the growing molecular glue industry.

Strategy + Tactics. Ahead of the BIO International Convention in June 2022, Messaginglab helped Degron Therapeutics refine their messages, define their target audience, and co-wrote and distributed a $22 million Series A financing announcement press release. Messaginglab also conducted phone and email outreach to reporters and delivered media reports to track coverage of the release.

Results. The funding announcement gained coverage from 377 total media outlets, including BioSpace, Endpoints News, BioWorld, Scrip, and Chemical and Engineering News, garnering over 6,000 views and putting Degron Therapeutics on the map in the molecular glue development space. Following the success of the funding release, Degron Therapeutics announced IND-enabling studies of its novel molecular glue preclinical candidate that degrades a previously “undruggable” RNA binding protein with indications in multiple solid tumors.

PAREXEL provides multiple clinical development services, and must constantly educate buyers on its offerings.

Strategy + Tactics. For more than five years, Messaginglab has supported this clinical research leader with marketing and content strategy. We write articles, brochures, datasheets, and white papers. These have covered topics as diverse as cancer immunotherapy, clinical trial supply chain, CNS drug development, data management, direct-to-patient trials, and global regulatory changes.

Results. Messaginglab’s marketing strategies and content have been essential for several multi-million dollar campaigns.

Tom Baruch invests in innovative early-stage businesses with a focus on synthetic biology, clean water, renewable energy, and smart grid solutions through Baruch Future Ventures. A pioneer in corporate venture capital, Baruch was one of the earliest investors to see the potential returns in applying biotechnology to real-world challenges. Baruch came to Messaginglab to refine his messaging and bring his thought leadership ideas to life.

Strategy + Tactics. Messaginglab worked with Baruch to generate a thought leadership strategy that included key messages, thought-leadership content, and publication.

Results. Messaginglab defined key messages that highlighted the driving force behind Baruch Future Ventures’ investment thesis, then created a series of thought leadership-focused articles for Baruch. The content, which was published on Greenbiz.com, covered a myriad of subjects including the intersection between energy, sustainability, and biotechnology and the importance of entrepreneurship in the face of climate change.

Messaginglab also helped Baruch draft “The Synthetic Biology Climate Change Opportunity,” a piece that explains the steps necessary for entrepreneurs to build a billion-dollar business in ten years. For more information on Tom Baruch, read Messaginglab’s exclusive interview on our blog.